SCHEMBL3768286

SCHEMBL3768286

CC(=O)c1ccc(N2CCN(CC(=O)N3CCN(C4CCC4)CC3)CC2=O)cc1

nearest known ligand 0.48

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 14/20 0.48
KCNH2 Q12809 4/20 0.46
HRH1 P35367 1/20 0.46
CYP2D6 P10635 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
PARP1 P09874 1/20 0.42
MAPK1 P28482 2/20 0.41
ALDH1A1 P00352 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767816 0.84 MEN1 (0.58) HRH3MEN1KMT2AMAPK1ALDH1A1
SCHEMBL3767465 0.81 MEN1 (0.58) HRH3MEN1KMT2AMAPK1ALDH1A1
SCHEMBL3769905 0.81 MEN1 (0.55) HRH3MEN1KMT2AMAPK1ALDH1A1
SCHEMBL3776934 0.81 MEN1 (0.57) HRH3MEN1KMT2AMAPK1ALDH1A1
SCHEMBL3773856 0.79 KMT2A (0.50) HRH3MEN1KMT2AMAPK1ALDH1A1
SCHEMBL3767679 0.77 HRH3 (0.57) HRH3MEN1KMT2APARP1MAPK1
SCHEMBL1018081 0.76 HRH3 (0.39) HRH3MEN1KMT2APARP1MAPK1
SCHEMBL1017656 0.76 HTT (0.39) HRH3MEN1KMT2APARP1MAPK1
SCHEMBL1017172 0.76 KDM2B (0.45) HRH3KCNH2PARP1ALDH1A1HTT
SCHEMBL14608866 0.75 PARP1 (0.38) HRH3KCNH2HRH1KMT2APARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
EP-1909797-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2008-04-16 EP disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 HRH3 2/4885KCNH2 130/4885HRH1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.